Reverse cholesterol transport: Its contribution to cholesterol catabolism in normal and disease states

Canadian Journal of Cardiology

Volumn 12, Issue 10, 1996, Pages 944-950

  Loh, Keh Chuan ^a   Tan, Meng Hee ^a  

^a DALHOUSIE UNIVERSITY   (Canada)

Author keywords

Apolipoprotein; Cholesterol esterification; Cholesteryl ester transfer protein; High density lipoprotein; Reverse cholesterol transport

Indexed keywords

APOLIPOPROTEIN; APOLIPOPROTEIN B; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; HIGH DENSITY LIPOPROTEIN; PHOSPHATIDYLCHOLINE STEROL ACYLTRANSFERASE;

ATHEROGENESIS; CHOLESTEROL TRANSPORT; CLINICAL OBSERVATION; DATA ANALYSIS; DATA BASE; HUMAN; LABORATORY; LIFESTYLE; LIVER METABOLISM; REVIEW;

APOLIPOPROTEINS; CARRIER PROTEINS; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEINS; DIABETES MELLITUS; GLYCOPROTEINS; HUMANS; HYPERLIPIDEMIAS; LIFE STYLE; LIPOPROTEINS, HDL; PHOSPHATIDYLCHOLINE-STEROL O-ACYLTRANSFERASE;

EID: 0029823486     PISSN: 0828282X     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Review

References (58)

1. Miller GJ, Miller NE. Plasma high density lipoprotein concentration and development of ischaemic heart disease. Lancet 1975;i:16-9.
2. Abbott RD, Wilson WFP, Kannel WB, Castelli WP. High density lipoprotein cholesterol, total cholesterol screening, and myocardial infarction, the Framingham Study. Arteriosclerosis 1988;8:207-11.
3. Gordon D, Rifkind BM. Current concepts: High density lipoproteins: the clinical implications of recent studies. N Engl J Med 1989;321:1311-5.
4. Glomset JA. The plasma lecithin:cholesterol acyltransferase reaction. J Lipid Res 1968;9:155-67.
5. Reicht D, Miller NE. Pathophysiology of reverse cholesterol transport: Insights from inherited disorders of lipoproteins metabolism. Arteriosclerosis 1989;9:785-92.
6. Miller NE. Raising high density lipoprotein cholesterol: The biochemical pharmacology of reverse cholesterol transport. Biochem Pharmacol 1990;40:403-10.
7. Lacko AG, Pritchard PH. 2nd International Symposium on Reverse Cholesterol Transport: Report on a meeting. J Lipid Res 1994;35:351-6.
8. Francone OL, Fielding CJ. Initial steps in reverse cholesterol transport: the role of short-lived cholesterol acceptors. Eur Heart J 1990;11(Suppl E):218-24.
9. Eisenberg S. High-density lipoprotein metabolism. J Lipid Res 1984;25:1017-58.
10. Tall AR. Plasma high-density lipoproteins: Metabolism and relationship to atherogenesis. J Clin Invest 1990;86:379-84.
11. Castro GR, Fielding CJ. Early incorporation of cell-derived cholesterol into pre-beta-migrating high-density lipoprotein. Biochemistry 1988;27:25-9.
12. Theret N, Delbart C, Aquie G, Fruchart J-C, Vassaux G, Ailhaud G. Cholesterol efflux from adipose cells is coupled to diacylglycerol production and protein kinase C production. Biochem Biophys Res Commun 1990;137:1361-8.
13. Barkia A, Puchois P, Ghalim N, Torpier G, Ailhaud G, Fruchart J-C. Differential role of apolipoprotein A-I containing particles in cholesterol efflux from adipose cells. Atherosclerosis 1991;87:135-46.
14. Hayek T, Oiknine J, Brook JG, Aviram M. Role of HDL apolipo-protein E in cellular cholesterol efflux: Studies in apo E knockout transgenic mice. Biochem Biophys Res Commun 1994;205:1072-8.
15. Oram JF, Mendez AJ, Slotte JP, Johnson TF. High-density lipoproteins mediate removal of sterol from intracellular pools, but not from plasma membranes of cholesterol loaded fibroblasts. Arterioscler Thromb 1991;11:403-14.
16. Fruchart J-C, Ailhaud G, Bard J-M. Heterogeneity of high density lipoprotein particles. Circulation 1993;87(Suppl III):22-7.
17. Sparks DL, Anantharamatah GM, Segrest JP, Phillips MC. Effect of the cholesterol content of reconstituted LpA-I on lecithin:cholesterol acyltransferase activity. J Biol Chem 1995;270:5151-7.
18. Francone OL, Gurakar A, Fielding CJ. Distribution and functions of lecithin-cholesterol acyltransferase and cholesterol ester-transfer protein in plasma lipoproteins. J Biol Chem 1989;264:7066-72.
19. Frohlich J, Westerlund J, Sparks D, Pritchard PH. Familial hypoalphalipoproteinemias. Clin Invest Med 1990;13:202-10.
20. Assmann G, von Eckardstein A, Funke H. High density lipoproteins, reverse transport of cholesterol, and coronary artery disease: Insights from mutations. Circulation 1993;87(Suppl III):28-34.
21. 58to Glu): Identification of an apolipoprotein C-III variant in a family with hyperalpha-lipoproteinemia. J Clin Invest 1991;87:1724-31.
22. Assmann G, von Eckardstein A, Funke H. Lecithin-cholesterol acyltransferase deficiency and fish-eye disease. Curr Opin Lipidol 1991;2:110-7.
23. Carlson LA, Philipson B. Fish-eye disease. A new familial condition with massive corneal opacities and dyslipoproteinaemia. Lancet 1979;ii:922-4.
24. Rader DJ, Ikewaki K, Duverger N, et al. Markedly accelerated catabolism of apolipoprotein A-II (ApoA-II) and high density lipoproteins containing ApoA-II in classic lecithin:cholesterol acyltransferase deficiency and fish-eye disease. J Clin Invest 1994;93:321-30.
25. Inazu A, Brown ML, Hesler CB, et al. Increased high-density lipoprotein levels caused by a common cholesteryl ester transfer protein gene mutation. N Engl J Med 1990;323:1234-8.
26. Akita H, Chiba H, Tsuchihashi K, et al. Cholesteryl ester transfer protein gene: two common mutations and their effect on plasma high-density lipoprotein cholesterol content. J Clin Endocrinol Metab 1994;79:1615-8.
27. Eto M, Miyata O, Noda K, Makino I. A family of homozygous familial hyperalphalipoproteinemia with complete deficiency of cholesteryl ester transfer activity. Artery 1990;17:202-12.
28. Connelly PW, Maguire GF, Lee M, Little JA. Plasma lipoproteins in familial hepatic lipase deficiency. Arteriosclerosis 1990;10:40-8.
29. Kantor MA, Cullinane EM, Sady SP, Herbert PN, Thompson PD. Excercise acutely increases high density lipoprotein cholesterol and lipoprotein lipase activity in trained and untrained men. Metabolism 1987;36:188-92.
30. Weintraub MS, Rosen Y, Otto R, Eisenberg S, Breslow JL. Physical exercise conditioning in the absence of weight loss reduces fasting and postprandial triglyceride-rich lipoprotein levels. Circulation 1989;79:1007-14.
31. Thompson PD, Cullinane EM, Sady SP, et al. Modest changes in high-density lipoprotein concentration and metabolism with prolonged exercise training. Circulation 1988,78:25-34.
32. Gupta AK, Ross EA, Myers JN, Kashyap ML. Increased reverse cholesterol transport in athletes. Metabolism 1993;42:684-90.
33. Amarasuriya RN, Gupta AK, Civen M, Horng YC, Maeda T, Kashyap ML. Ethanol stimulates apolipoprotein A-I secretion by human hepatocytes: implications for a mechanism for atherosclerosis protection. Metabolism 1992;41:827-32.
34. Puchois P, Ghalim N, Zylberberg G, Fievet P, Demarquilly C, Fruchart J-C. Effect of alcohol intake on human apolipoprotein A-I-containing lipoprotein subfractions. Arch Intern Med 1990;150:1638-41.
35. Hirano K, Matsuzawa Y, Sakai N, et al. Polydisperse low-density lipoproteins in hyperalphalipoproteinemic chronic alcohol drinkers in association with marked reduction of cholesteryl ester transfer protein activity. Metabolism 1992;41:1313-8.
36. Garrison RJ, Kannel WB, Feinleib M, Castelli WP, McNamara PM, Padgett SJ. Cigarette smoking and HDL cholesterol: the Framingham offspring study. Atherosclerosis 1978;30:17-25.
37. Haffner SM, Applebaum-Bowden D, Wahl PW, et al. Epidemiological correlates of high density lipoprotein subfractions, apolipoproteins A-I, A-II, and D, and lecithin cholesterol acyltransferase: effects of smoking, alcohol, and adiposity. Arteriosclerosis 1985;5:169-77.
38. deParscau L, Fielding CJ. Abnormal plasma cholesterol metabolism in cigarette smokers. Metabolism 1986;35:1070-3.
39. Fielding PE, Fielding CJ, Havel RJ, Kane JP, Tun P. Cholesterol net transport, esterification, and transfer in human hyperlipidemic plasma. J Clin Invest 1983;71:449-60.
40. Fielding CJ, Reaven GM, Liu G, Fielding PE. Increased free cholesterol in plasma low and very low density lipoproteins in non-insulin-dependent diabetes mellitus: its role in the inhibition of cholesteryl ester transfer. Proc Natl Acad Sci USA 1984;81:2512-6.
41. McCall MR, van den Berg JJM, Kuypers FA, et al. Modification of LCAT activity and HDL structure: new links between cigarette smoke and coronary heart disease risk. Arterioscler Thromb 1994;14:248-53.
42. Dieplinger H, Schoenfeld PY, Fielding CJ. Plasma cholesterol metabolism in end-stage renal disease. Difference between treatment by hemodialysis or peritoneal dialysis. J Clin Invest 1986;77:1071-83.
43. Ordonez JD, Hiatt RA, Killebrew EJ, Fireman BH. The increased risk of coronary heart disease associated with nephrotic syndrome. Kidney Int 1993;44:638-42.
44. Appel GB, Blum CB, Chien S, Kunis CL, Appel AS. The hyperlipidemia of the nephrotic syndrome. N Engl J Med 1985;312:1544-8.
45. Moulin P, Appel GB, Ginsberg HN, Tall AR. Increased concentration of plasma cholesteryl ester transfer protein in nephrotic syndrome: role in dyslipidemia. J Lipid Res 1992;33:1817-22.
46. Dunn FL. Plasma lipid and lipoprotein disorders in IDDM. Diabetes 1992;41(Suppl II):102-6.
47. Bagdade JD, Ritter MC, Subbaiah PV. Accelerated cholesteryl ester transfer in patients with insulin-dependent diabetes mellitus. Eur J Clin Invest 1991;21:161-7.
48. Selam JL, Kashyap ML, Gupta AK, et al. Alterations in reverse cholesterol transport associated with programmable implantable intraperitoneal insulin delivery. Metabolism 1994;43:665-9.
49. Fievet C, Theret N, Shojaee N, et al. Apolipoprotein A-I containing particles and reverse cholesterol transport in IDDM. Diabetes 1992;41:81-5.
50. Taskinen MR. Quantitative and qualitative lipoprotein abnormalities in diabetes mellitus. Diabetes 1992;41(Suppl II):12-7.
51. Fielding CJ, Reaven GM, Fielding PE. Human non-insulin-dependent diabetes: identification of a defect in plasma cholesterol transport normalized in vivo by insulin and in vitro by selective immunoabsorption of apolipoprotein E. Proc Natl Acad Sci USA 1982;79:6365-9.
52. Valdemarsson S, Hansson P, Hedner P, Nilsson-Ehle P. Relations between thyroid function, hepatic and lipoprotein lipase activities, and plasma lipoprotein concentrations. Acta Endocrinol (Copenh) 1983;104:50-6.
53. Dullaart RPF, Hoogenberg K, Groener JEM, Dikkeschi LD, Erkelens DW, Doorenbos H. The activity of cholesteryl ester transfer protein is decreased in hypothyroidism: a possible mechanism for an altered composition of high density lipoproteins. Eur J Clin Invest 1990;20:581-7.
54. Ritter MC, Kannan CR, Bagdade JD. The effects of hypothyroidism and replacement therapy on cholesteryl ester transfer. J Clin Endocrinol Metab 1996;81:797-800.
55. Dobiasova M, Stribrna J, Sparks DL, Pritchard PH, Frohlich JJ. Cholesterol esterification rates in very low density lipoprotein- and low density lipoprotein-depleted plasma. Relation to high density lipoprotein subspecies, sex, hyperlipidemia, and coronary artery disease. Arterioscler Thromb 1991;11:64-70.
56. 3 subclasses: study in hypertensive and normal middle-aged and septuagenarian men. J Lipid Res 1992;33:1411-8.
57. Dobiasova M, Frohlich JJ. Structural and functional assessment of high-density lipoprotein heterogeneity. Clin Chem 1994;40:1554-8.
58. Miller NE. Association of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am Heart J 1987;113:589-97.